FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

OMB APPROVAL Washington, D.C. 20549 OMB Number:

0104 Estimated average burden hours per 0.5

response:

3235-

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Trimarchi Thomas			2. Date of Requiring (Month/Da 07/23/20	Statement ay/Year)	3. Issuer Name and Ticker or Trading Symbol BridgeBio Pharma, Inc. [BBIO]						
(Last)	C/O BRIDGEBIO PHARMA, INC.				4. Relationship of Reportin Issuer (Check all applicable)	,	, , ,		5. If Amendment, Date of Original Filed (Month/Day/Year)		
3160 PORTER DR., SUITE 250 (Street) PALO ALTO (City) (State) (Zip)		_		Director Officer (give title below) President an	10% Owner Other (specify below)		6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person Form filed by More than One Reporting Person				
		1	Гable I - No	n-Derivat	ive Securities Benefi	icially Ov	vned				
1. Title of Security (Instr. 4)					2. Amount of Securities Beneficially Owned (Instr. 4)	Form: D	m: Direct Ov		. Nature of Indirect Beneficial wnership (Instr. 5)		
Common Stock				394,856	Г	D					
		(e. <u>ç</u>			e Securities Benefici ints, options, conver)			
E: (N			2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversio or Exercis		Form:	6. Nature of Indirect Beneficial Ownership (Instr.	
			Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Price of Derivative Security		Direct (D) or Indirect (I) (Instr. 5)	5)	
Stock Opt	ion (Right to l	Buy)	(1)	06/25/2029	Common Stock	115,000	17		D		
Stock Opt	ion (Right to l	Buy)	(2)	09/17/2030	Common Stock	16,419	42.19		D		
Stock Opt	ion (Right to l	Buy)	(3)	02/09/2031	Common Stock	22,145	68.8	87	D		
Stock Opt	ion (Right to 1	Buy)	(4)	12/01/2031	Common Stock	158,127	40.0	03	D		

Explanation of Responses:

- 1. The stock option is fully vested and exercisable. The stock option vested in 48 monthly installments from June 26, 2019 to June 26, 2023.
- 2. The stock option is fully vested and exercisable. The stock option vested as to 2,736 shares on October 18, 2020 and as to the remainder of the shares in 40 monthly installments thereafter through February 18, 2024.
- 3. 18,915 of the shares subject to this option are vested and exercisable. The option vests in 48 equal monthly installments from February 10, 2021 to February 10, 2025, subject to the Reporting Person's continued service to the Issuer through each such date.
- 4. 102,123 of the shares subject to this option are vested and exercisable. The option vested as to 25% of the shares on December 2, 2022 and as to the remainder of the shares in 36 monthly installments thereafter through December 2, 2025, subject to the Reporting Person's continued service to the Issuer through each such date.

Remarks:

Exhibit 24 - Power of Attorney

/s/ Brian C. Stephenson, Attorney-in-Fact

07/29/2024

** Signature of Reporting

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

LIMITED POWER OF ATTORNEY

The undersigned hereby constitutes and appoints each of Brian C. Stephenson and Adora Ndu, signing singly, and with full power of substitution, the undersigned's true and lawful attorney-in-fact to:

- (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of BridgeBio Pharma, Inc., a Delaware corporation (the "Company"), from time to time the following U.S. Securities and Exchange Commission ("SEC") forms: (i) Form ID, including any attached documents, to effect the assignment of codes to the undersigned to be used in the transmission of information to the SEC using the EDGAR System; (ii) Form 3, Initial Statement of Beneficial Ownership of Securities, including any attached documents; (iii) Form 4, Statement of Changes in Beneficial Ownership of Securities, including any attached documents; (iv) Form 5, Annual Statement of Beneficial Ownership of Securities in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder, including any attached documents; (v) Schedules 13D and 13G; and (vi) amendments of each thereof, in accordance with the Securities Exchange Act of 1934, as amended, and the rules thereunder, including any attached documents;
- (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5, Schedule 13D or 13G or any amendment(s) thereto, and timely file such form(s) with the SEC and any securities exchange, national association or similar authority; and
- (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact, acting singly, full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 or Regulation 13D-G of the Securities Exchange Act of 1934, as amended. The undersigned hereby agrees to indemnify the attorneys-in-fact and the Company from and against any demand, damage, loss, cost or expense arising from any false or misleading information provided by the undersigned to the attorneys-in-fact.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file such forms with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact. This Power of Attorney supersedes any prior power of attorney in connection with the undersigned's capacity as an officer and/or director of the Company. This Power of Attorney shall expire as to any individual attorney-in-fact if such attorney-in-fact ceases to be an employee of, or legal counsel to the Company.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of July 23, 2024.

<u>/s/ Thomas Trimarchi</u> Thomas Trimarchi